Cosentyx and Application site discoloration - a phase IV clinical study of FDA data

Summary:

Application site discoloration is reported as a side effect among people who take Cosentyx (secukinumab), especially for people who are female, 60+ old, also take Simvastatin, and have Psoriasis.

The phase IV clinical study analyzes which people have Application site discoloration when taking Cosentyx. It is created by eHealthMe based on reports of 187,010 people who have side effects when taking Cosentyx from the FDA, and is updated regularly.

What is Cosentyx?

Cosentyx has active ingredients of secukinumab. It is often used in psoriatic arthritis. eHealthMe is studying from 187,247 Cosentyx users. Check the latest studies of Cosentyx.

What is Application site discoloration?

Application site discoloration is found to be associated with 224 drugs and 434 conditions by eHealthMe. Check the latest studies of Application site discoloration.

On May, 03, 2026

187,010 people reported to have side effects when taking Cosentyx.
Among them, 18 people (0.01%) have Application site discoloration.

Could Cosentyx cause Application site discoloration?

Among these 18 people:

What is the gender of people who have Application site discoloration when taking Cosentyx? *

female: 88.89 %
male: 11.11 %

What is the age of people who have Application site discoloration when taking Cosentyx? *

What are other drugs people take besides Cosentyx? *

What are other side effects people have besides Application site discoloration? *

Malaise (a feeling of general discomfort or uneasiness): 16 people, 88.89%
Pain: 16 people, 88.89%
Itching: 14 people, 77.78%
Joint Pain: 13 people, 72.22%
Memory Loss: 12 people, 66.67%
Cough: 11 people, 61.11%
Dyspnea (difficult or laboured breathing): 10 people, 55.56%
Pneumonia: 10 people, 55.56%
Diabetes: 10 people, 55.56%
Pain In Extremity: 9 people, 50.00%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 9 people, 50.00%
High Blood Pressure: 8 people, 44.44%
Ankylosing Spondylitis (type of arthritis affecting the spine): 8 people, 44.44%
Uveitis (inflammation of the uvea): 7 people, 38.89%
Sleep Disorder: 7 people, 38.89%
High Blood Cholesterol: 7 people, 38.89%
Arrhythmias (irregular heartbeat): 7 people, 38.89%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 22.22%
Cardiac Disorder: 4 people, 22.22%
Pneumonia: 3 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cosentyx and have Application site discoloration?

- Check whether Application site discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cosentyx:

Cosentyx (187,247 reports)

Browse all side effects of Cosentyx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site discoloration:

Application site discoloration (224 drugs)

Browse all the conditions that are associated with Application site discoloration:

Application site discoloration (434 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on secukinumab (the active ingredients of Cosentyx) and Cosentyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.